Evolution of antifungal-drug resistance: Mechanisms and pathogen fitness

Nature Reviews Microbiology

Volumn 3, Issue 7, 2005, Pages 547-556

  Anderson, James B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOSPORIN; ERGOSTEROL; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; TACROLIMUS; TERBINAFINE;

ANTIBIOTIC RESISTANCE; CANDIDA ALBICANS; CELL VIABILITY; DRUG STRUCTURE; DRUG TARGETING; FUNGAL GENETICS; FUNGAL VIRULENCE; FUNGUS GROWTH; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; MICROBIAL POPULATION DYNAMICS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MECHANICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES CEREVISIAE;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; EPISTASIS, GENETIC; EVOLUTION; FORECASTING; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; SACCHAROMYCES CEREVISIAE; VIRULENCE;

CANDIDA ALBICANS; FUNGI; SACCHAROMYCES CEREVISIAE;

EID: 21344451158     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro1179     Document Type: Review

References (65)

1. Sanglard, D. & Odds, F. C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2, 73-85 (2002).
2. Baldauf, S. L., Roger, A. J., Wenk-Siefert, I. & Doolittle, W. F. A kingdom-level phylogeny of eukaryotes based on combined protein data. Science 290, 972-977 (2000).
3. Sanglard, D. Resistance of human fungal pathogens to antifungal drugs. Curr. Opin. Microbiol. 5, 379-385 (2002).
4. Lupetti, A., Danesi, R., Campa, M., Del Tacca, M. & Kelly, S. Molecular basis of resistance to azole antifungals. Trends Mol. Med. 8, 76-81 (2002).
5. Cowen, L. E. et al. Population genomics of drug resistance in Candida albicans. Proc. Natl Acad. Sci. USA 99, 9284-9928 (2002).
6. Barker, K. S. et al. Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. J. Antimicrob. Chemother. 54, 376-385 (2004).
7. DeRisi, J. et al. Genome microarray analysis of transcriptional activation in multidrug resistance yeast mutants. FEBS Lett. 470, 156-160 (2000).
8. Rogers, P. D. & Barker, K. S. Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. Antimicrob. Agents Chemother. 47, 1220-1227 (2003).
9. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pennsylvania (1997).
10. Casadevall, A. & Profski, L. A. The damage-response framework of microbial pathogenesis. Nature Rev. Microbiol. 1, 17-24 (2003).
11. Cowen, L. E., Kohn, L. M. & Anderson, J. B. Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans. J. Bacteriol. 183, 2971-2978 (2001).
12. Anderson, J. B. et al. Mode of selection and experimental evolution of antifungal drug resistance in Saccharomyces cerevisiae. Genetics 163, 1287-1298 (2003).
13. Pfaller, M. A., Sheehan, D. J. & Rex, J. H. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin. Microbiol. Rev. 17, 268-280 (2004).
14. Matsumori, N., Yamaji, N., Matsuoka, S., Oishi, T. & Murata, M. Amphotericin B covalent dimers forming sterol-dependent ion-permeable membrane channels. J. Am. Chem. Soc. 124, 4180-4181 (2002).
15. White, T. C., Marr, K. A. & Bowden, R. A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11, 382-402 (1998).
16. Kurtz, M. B. et al. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect. Immun. 64, 3244-3251 (1996).
17. Hernandez, S. et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. 48, 1382-1383 (2004).
18. Levin, B. R. & Bergstrom, C. T. Bacteria are different: observations, interpretations, speculations, and opinions about the mechanisms of adaptive evolution in prokaryotes. Proc. Natl Acad. Sci. USA 97, 6981-6985 (2000).
19. Fincham, J. R. S., Day, P. R. & Radford, A. Fungal Genetics 4th edn (University of California Press, Berkeley, 1979)
20. Pfaller, M. A. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin. Infect. Dis. 22, S89-S94 (1996).
21. Pontecorvo, G. The parasexual cycle in fungi. Annu. Rev. Microbiol. 10, 393-400 (1956).
22. Milgroom, M. G. Recombination and the multilocus structure of fungal populations. Annu. Rev. Phytopathology 34, 457-477 (1996).
23. Anderson, J. B. & Kohn, L. M. Genotyping, gene genealogies, and genomics bring fungal population genetics above ground. Trends Ecol. Evol. 13, 444-449 (1998).
24. Anderson, J. B. et al. Infrequent genetic exchange and recombination in the mitochondrial genome of Candida albicans. J. Bacteriol. 183, 865-872 (2001).
25. Burt, A., Carter, D. A., Koenig, G. L., White, T. J. & Taylor, J. W. Molecular markers reveal cryptic sex in the human pathogen Coccidioides immitis. Proc. Natl Acad. Sci. USA 93, 770-773 (1996).
26. Graser, Y. et al. Molecular markers reveal that population structure of the human pathogen Candida albicans exhibits both clonality and recombination. Proc. Natl Acad. Sci. USA 93, 12473-12477 (1996).
27. Taylor, J. W., Geiser, D. M., Burt, A. & Koufopanou, V. The evolutionary biology and population genetics underlying fungal strain typing. Clin. Microbiol. Rev. 12, 126-146 (1999).
28. Taylor, J. W. et al. Phylogenetic species recognition and species concepts in fungi. Fungal Genet. Biol. 31, 21-32 (2000).
29. White, T. C. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41, 1482-1487 (1997).
30. Elena, S. F. & Lenski, R. E. Evolution experiments with microorganisms: the dynamics and genetic bases of adaptation. Nature Rev. Genet. 4, 457-469 (2003).
31. Zeyl, C. Budding yeast as a model organims for population genetics. Yeast 16, 773-784 (2000).
32. Andersson, D. I. Persistence of antibiotic resistant bacteria. Curr. Opin. Microbiol. 6, 452-456 (2003).
33. Levin, B. R., Perrot, V. & Walker, N. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154, 985-997 (2000).
34. Maisnier-Patin, S. & Andersson, D. I. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res. Microbiol. 155, 360-369 (2004).
35. Paquin, C. & Adams, J. Frequency of fixation of adaptive mutations is higher in evolving diploid than haploid yeast populations. Nature 302, 495-500 (1983).
36. Cowen, L. E. et al. Evolution of drug resistance in experimental populations of Candida albicans. J. Bacteriol. 182, 1515-1522 (2000).
37. Hall, B. G. Innovation: predicting the evolution of antibiotic resistance genes. Nature Rev. Microbiol. 2, 430-435 (2004).
38. Sanglard, D., Ischer, F., Koymans, L. & Bille, J. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42, 241-253 (1998).
39. White, T. C. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14α demethylase in Candida albicans. Antimicrob. Agents Chemother. 41, 1488-1494 (1997).
40. Markovich, S., Yekutiel, A., Shalit, I., Shadkchan, Y. & Osherov, N. Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 48, 3871-3876 (2004).
41. Kondrashov, A. S. Classification of hypotheses on the advantage of amphimixis. J. Hered. 84, 372-387 (1993).
42. Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R. & Rex, J. H. Combination antifungal therapy. Antimicrob. Agents Chemother. 48, 693-715 (2004).
43. Singh, N. & Heitman, J. Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients. Transplantation 77, 795-800 (2004).
44. Cruz, M. C. et al. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J. 21, 546-559 (2002).
45. Sanglard, D., Ischer, F., Marchetti, O., Entenza, J. & Bille, J. Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol. Microbiol. 48, 959-976 (2003).
46. Matthews, R. C. & Burnie, J. P. Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 22, 865-871 (2004).
47. Vazquez, J. A. Combination antifungal therapy against Candida species: the new frontier - are we there yet? Med. Mycol. 41, 355-368 (2003).
48. Kontoyiannis, D. P. & Lewis, R. E. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist. Updat. 6, 257-269 (2003).
49. Cuenca-Estrella, M. Combinations of antifungal agents in therapy - what value are they? J. Antimicrob. Chemother. 54, 854-869 (2004).
50. Anderson, J. B., Ricker, N. & Sirjusingh, C. Ploidy and evolution of antifungal drug resistance. Genetics 168, 1915-1923 (2004).
51. Kirschner, M. & Gerhart, J. Evolvability. Proc. Natl Acad. Sci. USA 95, 8420-8427 (1998).
52. Funk & Wagnall's Standard College Dictionary (Harcourt, Brace & World Inc., New York, 1963).
53. Zeyl, C. Capturing the adaptive mutation in yeast. Res. Microbiol. 155, 217-223 (2004).
54. Saupe, S. J. Molecular genetics of heterokaryon incompatibility in filamentous ascomycetes. Microbiol. Mol. Biol. Rev. 64, 489-502 (2000).
55. Glass, N. L. & Kaneko, I. Fatal attraction: nonself recognition and heterokaryon incompatibility in filamentous fungi. Eukaryot. Cell 2, 1-8 (2003).
56. Cortesi, P., McCulloch, C. E., Song, H., Lin, H. & Milgroom, M. G. Genetic control of horizontal virus transmission in the chestnut blight fungus, Cryphonectria parasitica. Genetics 159, 107-118 (2001).
57. Fraser, J. A. & Heitman, J. Evolution of fungal sex chromosomes. Mol. Microbiol. 51, 299-306 (2004).
58. Casselton, L. A. & Olesnicky, N. S. Molecular genetics of mating recognition in basidiomycete fungi. Microbiol. Mol. Biol. Rev. 62, 55-70 (1998).
59. Herskowitz, I. Life cycle of the budding yeast Saccharomyces cerevisiae. Microbiol. Rev. 52, 536-553 (1988).
60. Kronstad, J. W. & Staben, C. Mating type in filamentous fungi. Annu. Rev. Genet. 31, 245-276 (1997).
61. Lockhart, S. R., Daniels, K. J., Zhao, R., Wessels, D. & Soll, D. R. Cell biology of mating in Candida albicans. Eukaryot. Cell 2, 49-61 (2003).
62. Hull, C. M., Raisner, R. M. & Johnson, A. D. Evidence for mating of the 'asexual' yeast Candida albicans in a mammalian host. Science 289, 307-310 (2000).
63. Miller, M. G. & Johnson, A. D. White-opaque switching in Candida albicans is controlled by mating-type locus homeodomain proteins and allows efficient mating. Cell 110, 293-302 (2002).
64. Magee, B. B. & Magee, P. T. Induction of mating in Candida albicans by construction of MTLa and MTLα strains. Science 289, 310-313 (2000).
65. Tsong, A. E., Miller, M. G., Raisner, R. M. & Johnson, A. D. Evolution of a combinatorial transcriptional circuit: a case study in yeasts. Cell 115, 389-399 (2003).